Intralesional hyaluronidase injection to relieve non-hyaluronic acid filler-induced vascular adverse events.
Jonathan A KadouchLeonie SchelkeOlivier GrohVicky SokolPeter VelthuisPublished in: International journal of dermatology (2024)
Unlike the mechanical hypothesis, which assumes filler particles travel antegrade to block arterioles in a large skin area, we hypothesize vasoconstriction as the pivot in VAEs. Filler injection-induced spasms could lead to long-lasting vasoconstriction of the perforator arteries stemming from the central facial arteries. Our results underscore that perforasome vasoconstriction might be the leading cause of the ischemia and subsequent necrosis in VAEs and that relaxation of these perforasomes, rather than dissolving the filler material, resolves the clinical symptoms associated with VAEs.